03.14.12
VasoStitch, based in Danville, Calif., has established its Scientific Advisory Board with the appointment of Willam Fearon, M.D., and Chaim Lotan, M.D., as its first members.
Current surgical arterial or cardiac access and closure for large-diameter, catheter-based intervention such as TAVR (transcatheter aortic valve replacement) adds up to an hour to an already long, complex procedure.
A device that can replicate the current gold standard of surgical access-and-closure but in a quicker and easier-to-use fashion would reduce healthcare costs dramatically, enhance adoption of large diameter cardiovascular and endovascular therapies, and improve the efficiency of patient management, according to VasoStitch, which is developing non-surgical transfemoral and transapical access-and-closure systems for minimally invasive heart valve replacement.
“Presently, surgical cut-down and suturing of the femoral artery is the most common approach for larger-diameter percutaneous vascular procedures, but this is not ideal,” said Fearon, associate professor for Cardiovascular Medicine, Stanford University School of Medicine in Palo Alto, Calif.
Lotan, director of The Heart Institute, Hadassah University Hospital, Jerusalem, Israel, said: “It is logical to assume that increased patient throughput and simplified scheduling will be additional payer and hospital benefits that would facilitate fast adoption of the VasoStitch systems."
“We are extremely proud to establish the VasoStitch scientific advisory board with the appointment of two preeminent cardiologists,” said Amir Belson, M.D., founder and chairman of VasoStitch. Belson previously founded NeoGuide Systems, a company that developed platform technology for minimally invasive surgical procedures and was acquired by Intuitive Surgical in 2009.
Current surgical arterial or cardiac access and closure for large-diameter, catheter-based intervention such as TAVR (transcatheter aortic valve replacement) adds up to an hour to an already long, complex procedure.
A device that can replicate the current gold standard of surgical access-and-closure but in a quicker and easier-to-use fashion would reduce healthcare costs dramatically, enhance adoption of large diameter cardiovascular and endovascular therapies, and improve the efficiency of patient management, according to VasoStitch, which is developing non-surgical transfemoral and transapical access-and-closure systems for minimally invasive heart valve replacement.
“Presently, surgical cut-down and suturing of the femoral artery is the most common approach for larger-diameter percutaneous vascular procedures, but this is not ideal,” said Fearon, associate professor for Cardiovascular Medicine, Stanford University School of Medicine in Palo Alto, Calif.
Lotan, director of The Heart Institute, Hadassah University Hospital, Jerusalem, Israel, said: “It is logical to assume that increased patient throughput and simplified scheduling will be additional payer and hospital benefits that would facilitate fast adoption of the VasoStitch systems."
“We are extremely proud to establish the VasoStitch scientific advisory board with the appointment of two preeminent cardiologists,” said Amir Belson, M.D., founder and chairman of VasoStitch. Belson previously founded NeoGuide Systems, a company that developed platform technology for minimally invasive surgical procedures and was acquired by Intuitive Surgical in 2009.